Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for EXJADE
- Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease
- Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
- Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
- Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
- A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.
- The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
- Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
- Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
- Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
- Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
- Treatment of Iron Overload Requiring Chelation Therapy
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
- Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
- A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS
- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
- Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
- Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
- Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
- Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia
- Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
- Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
- The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
- Exjade-Early-Trial
- Clinical Importance of Treating Iron Overload in Sickle Cell Disease
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
- Pilot Study for Patients With Poor Response to Deferasirox
- Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
- Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
- Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
- Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
- Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Clinical trials list
click for details